These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 25011422)
41. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Sempere AP; Berenguer-Ruiz L; Feliu-Rey E Eur J Neurol; 2013 Aug; 20(8):e109-10. PubMed ID: 23829238 [No Abstract] [Full Text] [Related]
42. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Tanasescu R; Constantinescu CS Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791 [TBL] [Abstract][Full Text] [Related]
43. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Cohen JA; Barkhof F; Comi G; Izquierdo G; Khatri B; Montalban X; Pelletier J; Eckert B; Häring DA; Francis G J Neurol; 2013 Aug; 260(8):2023-32. PubMed ID: 23632946 [TBL] [Abstract][Full Text] [Related]
44. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810 [TBL] [Abstract][Full Text] [Related]
45. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Warnke C; Wiendl H; Hartung HP; Stüve O; Kieseier BC Drug Des Devel Ther; 2010 Jul; 4():117-26. PubMed ID: 20689698 [TBL] [Abstract][Full Text] [Related]
46. Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. Patrucco L; Cristiano E; Sánchez F; Miguez J; Rojas JI Clin Neuropharmacol; 2019; 42(5):163-166. PubMed ID: 31348014 [TBL] [Abstract][Full Text] [Related]
47. Switching from natalizumab to fingolimod: an observational study. Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398 [TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065 [TBL] [Abstract][Full Text] [Related]
49. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Ward MD; Jones DE; Goldman MD Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480 [TBL] [Abstract][Full Text] [Related]
50. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
51. Fingolimod for the treatment of relapsing multiple sclerosis. Singer BA Expert Rev Neurother; 2013 Jun; 13(6):589-602. PubMed ID: 23738997 [TBL] [Abstract][Full Text] [Related]
52. Fingolimod-associated amenorrhea: a report of three cases. Alroughani R Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730 [TBL] [Abstract][Full Text] [Related]
53. [Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)]. Fernández Ó; Rodríguez-Antigüedad A; Oreja-Guevara C; Garcia-Garcia M; Montalban X; Rev Neurol; 2014 Jan; 58(2):77-83. PubMed ID: 24399624 [TBL] [Abstract][Full Text] [Related]
54. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419 [TBL] [Abstract][Full Text] [Related]
55. The effectiveness of fingolimod in a Portuguese real-world population. Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621 [TBL] [Abstract][Full Text] [Related]
56. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Hoepner R; Havla J; Eienbröker C; Tackenberg B; Hellwig K; Meinl I; Hohlfeld R; Gold R; Kümpfel T; Kleiter I Mult Scler; 2014 Nov; 20(13):1714-20. PubMed ID: 24842961 [TBL] [Abstract][Full Text] [Related]
57. Fingolimod in a patient with Wolff-Parkinson-White syndrome. Huys AC; Lalive PH; Sekoranja L Mult Scler; 2014 Apr; 20(5):636-7. PubMed ID: 23897641 [No Abstract] [Full Text] [Related]
58. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445 [TBL] [Abstract][Full Text] [Related]
59. [Fingolimod treatment in multiple sclerosis]. Tanaka M Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386 [TBL] [Abstract][Full Text] [Related]
60. Fingolimod for multiple sclerosis: a review for the specialist nurse. Harrison K Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]